Literature DB >> 23918977

Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.

Laurent Verkoczy1, Yao Chen, Jinsong Zhang, Hilary Bouton-Verville, Amanda Newman, Bradley Lockwood, Richard M Scearce, David C Montefiori, S Moses Dennison, Shi-Mao Xia, Kwan-Ki Hwang, Hua-Xin Liao, S Munir Alam, Barton F Haynes.   

Abstract

A goal of HIV-1 vaccine development is to elicit broadly neutralizing Abs (BnAbs). Using a knock-in (KI) model of 2F5, a human HIV-1 gp41 membrane proximal external region (MPER)-specific BnAb, we previously demonstrated that a key obstacle to BnAb induction is clonal deletion of BnAb-expressing B cells. In this study of this model, we provide a proof-of-principle that robust serum neutralizing IgG responses can be induced from pre-existing, residual, self-reactive BnAb-expressing B cells in vivo using a structurally compatible gp41 MPER immunogen. Furthermore, in CD40L-deficient 2F5 KI mice, we demonstrate that these BnAb responses are elicited via a type II T-independent pathway, coinciding with expansion and activation of transitional splenic B cells specific for 2F5's nominal gp41 MPER-binding epitope (containing the 2F5 neutralization domain ELDKWA). In contrast, constitutive production of nonneutralizing serum IgGs in 2F5 KI mice is T dependent and originates from a subset of splenic mature B2 cells that have lost their ability to bind 2F5's gp41 MPER epitope. These results suggest that residual, mature B cells expressing autoreactive BnAbs, like 2F5 as BCR, may be limited in their ability to participate in T-dependent responses by purifying selection that selectively eliminates reactivity for neutralization epitope-containing/mimicked host Ags.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23918977      PMCID: PMC3870053          DOI: 10.4049/jimmunol.1300971

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

Review 1.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Authors:  Barton F Haynes; M Anthony Moody; Laurent Verkoczy; Garnett Kelsoe; S Munir Alam
Journal:  Hum Antibodies       Date:  2005

2.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

Review 3.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

4.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

5.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.

Authors:  Rosa M F Cardoso; Michael B Zwick; Robyn L Stanfield; Renate Kunert; James M Binley; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Immunity       Date:  2005-02       Impact factor: 31.745

6.  The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.

Authors:  S Munir Alam; Mildred McAdams; David Boren; Michael Rak; Richard M Scearce; Feng Gao; Zenaido T Camacho; Daniel Gewirth; Garnett Kelsoe; Pojen Chen; Barton F Haynes
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

7.  Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Authors:  Barton F Haynes; Judith Fleming; E William St Clair; Herman Katinger; Gabriela Stiegler; Renate Kunert; James Robinson; Richard M Scearce; Kelly Plonk; Herman F Staats; Thomas L Ortel; Hua-Xin Liao; S Munir Alam
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

8.  Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Authors:  S Munir Alam; Richard M Scearce; Robert J Parks; Kelly Plonk; Steven G Plonk; Laura L Sutherland; Miroslaw K Gorny; Susan Zolla-Pazner; Stacie Vanleeuwen; M Anthony Moody; Shi-Mao Xia; David C Montefiori; Georgia D Tomaras; Kent J Weinhold; Salim Abdool Karim; Charles B Hicks; Hua-Xin Liao; James Robinson; George M Shaw; Barton F Haynes
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 9.  Sites and stages of autoreactive B cell activation and regulation.

Authors:  Mark J Shlomchik
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

Review 10.  B-cell anergy: from transgenic models to naturally occurring anergic B cells?

Authors:  John C Cambier; Stephen B Gauld; Kevin T Merrell; Barbara J Vilen
Journal:  Nat Rev Immunol       Date:  2007-07-20       Impact factor: 53.106

View more
  57 in total

1.  HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.

Authors:  Yuge Wang; Pratibha Kapoor; Robert Parks; Aaron Silva-Sanchez; S Munir Alam; Laurent Verkoczy; Hua-Xin Liao; Yingxin Zhuang; Peter Burrows; Michael Levinson; Ada Elgavish; Xiangqin Cui; Barton F Haynes; Harry Schroeder
Journal:  Immunogenetics       Date:  2015-12-19       Impact factor: 2.846

2.  Bill and Melinda Gates honored with Lasker~Bloomberg Public Service Award.

Authors:  Sarah Jackson
Journal:  J Clin Invest       Date:  2013-09-09       Impact factor: 14.808

Review 3.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

4.  DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Authors:  Sachin Gupta; Emily S Clark; James M Termini; Justin Boucher; Saravana Kanagavelu; Celia C LeBranche; Sakhi Abraham; David C Montefiori; Wasif N Khan; Geoffrey W Stone
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

5.  Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer.

Authors:  Patrick N Reardon; Harvey Sage; S Moses Dennison; Jeffrey W Martin; Bruce R Donald; S Munir Alam; Barton F Haynes; Leonard D Spicer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

6.  Redemption of autoreactive B cells.

Authors:  Barton F Haynes; Laurent Verkoczy; Garnett Kelsoe
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-11       Impact factor: 11.205

Review 7.  Designing synthetic vaccines for HIV.

Authors:  Alberto Fernández-Tejada; Barton F Haynes; Samuel J Danishefsky
Journal:  Expert Rev Vaccines       Date:  2015-03-31       Impact factor: 5.217

Review 8.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

9.  AIDS/HIV. Host controls of HIV neutralizing antibodies.

Authors:  Barton F Haynes; Laurent Verkoczy
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

10.  Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Authors:  Jinsong Zhang; S Munir Alam; Hilary Bouton-Verville; Yao Chen; Amanda Newman; Shelley Stewart; Frederick H Jaeger; David C Montefiori; S Moses Dennison; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2014-01-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.